DALLAS, Aug. 21, 2006 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has initiated Profile Coverage of Complete Care Medical, Inc. (Pink Sheets:CCMI). Complete Care Medical is a Delaware corporation formed in 2005. CCMI has acquired two companies including CarePharm, LLC, which was acquired on June 2005, and Diabetes Gold, Inc. which was acquired in June 2005. The company also recently announced they are launching a new division focusing on disease specific products and services pertaining to the Urological segment of the healthcare industry. CCMI's newest division will focus on specific products within a $3.3 Billion per year niche market. CCMI believes they have the management, marketing, fulfillment and distribution mechanism now in place to be successful in going after a significant portion of this emerging market. They will be launching a new and innovative product in the urology sector in September which already has FDA approval and they will be able to ship this product immediately and the gross margins on this new product are exceptional.
Complete Care Medical, Inc., provides patients in all 50 states with lower-cost alternatives for disease management, medical supplies and prescription pharmaceuticals. In addition, Complete Care Medical's discount services and medication program offers healthcare payers, healthcare providers, healthcare professionals and patients with easy access to utilization and compliance data in order to improve patient outcomes and improve quality of life.
The CCMI business model is based upon mutual patient referrals among its subsidiary medical companies. This affords the opportunity to sell a suite of medical products and services to each patient, rather than a single product from a single company. For example, a typical diabetes patient uses more than $3,000 in prescription drugs annually. So it follows that Diabetes Gold, Inc., CCMI's diabetes management subsidiary should refer each of its diabetes patients to CarePharm, CCMI's mail order pharmacy subsidiary, and CarePharm should in turn refer each of its diabetes patients, spending at least $250 annually on diabetes supplies, to Diabetes Gold for diabetes supplies and services. This same scenario will also apply to their new urology product, in that the typical urology patient requires 7 to 9 different medications each month, which the company's mail order pharmacy can supply as well.
To view the StockGuru.com Profile for Complete Care Medical, Inc., please visit:
http://www.stockguru.com/profiles/ccmi/index.php
About StockGuru.com
StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at (469) 252-3031 or email publisher@stockguru.com. Our services include our Morning, Midday, and After The Bell news releases. Additionally, we profile publicly traded companies on our web site, we do interviews with CEOs or other key executives on our web site, and we have our financial writers cover our companies.
Forward-Looking Statements: This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties.
All information in this release is as of the date of this release. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.
Disclosure: Pentony Enterprises LLC was compensated two million free trading shares from a non-controlling third party for profile coverage. John Pentony, a Principle of Pentony Enterprises, also owns 912,000 shares previously accumulated by buying in the open market. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. All shares -- including those previously accumulated in the open market -- will be held for at least thirty days from the initial date of publication, which is August 18, 2006. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.